University of Washington, Seattle, Washington, USA.
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Br J Haematol. 2022 May;197(3):306-309. doi: 10.1111/bjh.18088. Epub 2022 Feb 18.
Prior reports evaluating SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia (CLL) used semiquantitative measurements of anti-S to evaluate immunity; however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and lower anti-S levels compared to healthy controls. Notably, we demonstrated similar results with the Roche anti-S assay and neutralization activity. Durable responses were seen at six months; augmentation with boosters was possible in responding patients. Absence of normal B cells, frequently seen in patients receiving Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, was a strong predictor of lack of seroconversion.
先前有研究报告评估了 SARS-CoV-2 疫苗在慢性淋巴细胞白血病（CLL）中的疗效，这些研究使用抗-S 的半定量测量来评估免疫；然而，在导致疫苗批准的试验中，使用了中和测定来评估功能性免疫。在这里，我们发现接种疫苗的 CLL 患者的血清转化率降低，并且与健康对照相比，抗-S 水平较低。值得注意的是，我们使用罗氏抗-S 测定法和中和活性得到了类似的结果。六个月时观察到持久的反应；在有反应的患者中，使用加强针进行增强是可能的。经常在接受布鲁顿酪氨酸激酶和 B 细胞淋巴瘤 2 抑制剂治疗的患者中观察到的正常 B 细胞缺失是血清转化率低的强烈预测指标。
